
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio Inc. is positioned favorably with its innovative ADI-001 therapy showing significant efficacy in lupus nephritis and systemic lupus erythematosus, indicating strong potential in treating autoimmune diseases alongside oncology targets. The initiation of a Phase 1 study for ADI-212 in metastatic castration-resistant prostate cancer in 2026, with data expected later that year, suggests upcoming value inflection points that could enhance the company's growth trajectory. Additionally, the plan to utilize third-party manufacturers for commercial-scale production is expected to mitigate manufacturing risks, supporting a more reliable path to market for their therapies.
Bears say
Adicet Bio Inc. faces significant financial challenges, projecting a net loss of $1.13 per share for 2025, indicating concerns about its profitability. The company’s pipeline, particularly the ADI-001 candidate, may suffer from lower-than-expected efficacy and increased regulatory risks, as no FDA-approved therapies exist for Vδ1 gamma-delta T cells, contributing to a cautious outlook. Additionally, potential setbacks in clinical development, competition affecting market share, and long-term dilution risks further exacerbate the negative financial projections for Adicet Bio's stock.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares